Aptevo Therapeutics Inc (NASDAQ:APVO) CEO Marvin L. White purchased 30,000 shares of the business’s stock in a transaction on Monday, May 20th. The shares were purchased at an average price of $0.81 per share, with a total value of $24,300.00. Following the acquisition, the chief executive officer now directly owns 243,603 shares in the company, valued at $197,318.43. The acquisition was disclosed in a filing with the SEC, which is available through this link.
NASDAQ APVO traded down $0.02 during trading on Monday, hitting $0.77. 409,286 shares of the stock traded hands, compared to its average volume of 478,124. The stock has a market capitalization of $36.08 million, a PE ratio of -0.32 and a beta of 2.64. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.15 and a quick ratio of 2.66. Aptevo Therapeutics Inc has a 12-month low of $0.67 and a 12-month high of $6.09.
Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $7.02 million during the quarter, compared to analyst estimates of $6.30 million. Aptevo Therapeutics had a negative return on equity of 122.33% and a negative net margin of 199.24%. On average, analysts anticipate that Aptevo Therapeutics Inc will post -1.39 EPS for the current fiscal year.
Several equities analysts have weighed in on the company. Zacks Investment Research cut Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. ValuEngine cut Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Piper Jaffray Companies raised their price target on Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $7.88.
Several large investors have recently bought and sold shares of APVO. Dimensional Fund Advisors LP lifted its stake in shares of Aptevo Therapeutics by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock valued at $7,242,000 after purchasing an additional 73,911 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Aptevo Therapeutics by 4.8% in the 4th quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 21,059 shares during the last quarter. Clifford Swan Investment Counsel LLC bought a new stake in shares of Aptevo Therapeutics in the 4th quarter valued at approximately $35,000. Deutsche Bank AG lifted its stake in shares of Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 236,300 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Aptevo Therapeutics in the 1st quarter valued at approximately $33,000. 17.07% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Aptevo Therapeutics Inc (APVO) CEO Marvin L. White Buys 30,000 Shares” was originally published by Highlight Press and is owned by of Highlight Press. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://highlightpress.com/2019/05/20/aptevo-therapeutics-inc-apvo-ceo-marvin-l-white-buys-30000-shares.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Further Reading: What is Blockchain?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.